GlucoTrack's Lokahi Therapeutics disclosed its first external, fee-for-service partnership with Innovate GBM, a glioblastoma-focused nonprofit. Innovate GBM will tap Lokahi's AI-driven asset-identification pipeline, built on 14 university collaborations, to screen brain-tumor assets for licensing and development, potentially creating near-term revenue visibility for GCTK though terms are not disclosed.
GCTK stock rose 59.9% after strong clinical study results. The study showed excellent accuracy for the Continuous Blood Glucose Monitor. 92% of measurements were accurate, validating the device's safety and performance. A long-term feasibility study is planned for Q3 2025. GCTK offers a less invasive alternative to traditional glucose monitors.
